Antitrust Antitrust

Teva goes to EU court over Cephalon antitrust fine

By Lewis Crofts
  • 11 Feb 2021 04:47
  • 11 Feb 2021 05:15
Teva filed an EU court appeal this month to contest a fine of 60.5 million euros ($73 million) imposed on it and Cephalon for delaying the market entry of a cheaper drug to treat sleep disorders.
In November, the European Commission wrapped up a probe into a 2005 agreement between Teva

To view the latest version of this document and thousands of others like it, sign-in to MLex or register for a free trial.

Lewis Crofts

Editor-In-Chief


Lewis leads MLex's editorial strategy, content direction, quality and development. He has a reputation for breaking stories and providing analysis on complex legal disputes before regulators and courts around the globe. He has also developed MLex's unrivalled coverage of competition policy, litigation, regulation, Brexit and international investigations.

Discover MLex

Stay on top of global regulatory developments

Latest News